ADVENTRX Pharmaceuticals Announces Closing of...(tion or qualification under the securiti...)

Date:6/15/2009

tion or qualification under the securities laws of any such state or jurisdiction. The securities may only be offered by means of a prospectus. Copies of the prospectus supplement and accompanying base prospectus can be obtained directly from ADVENTRX at 6725 Mesa Ridge Road, Suite 100, San Diego, California 92121 or from the SEC's website at www.sec.gov.

About ADVENTRX Pharmaceuticals Inc.

ADVENTRX Pharmaceuticals is a biopharmaceutical company whose product candidates are designed to improve the safety and commercial potential of existing cancer treatments. More information can be found on the Company's web site at www.adventrx.com.

Forward Looking Statement

ADVENTRX cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks and assumptions that, if they materialize or do not prove to be accurate, could cause ADVENTRX's results to differ materially from historical results or those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that ADVENTRX will be unable to raise sufficient additional capital on a timely basis to continue as a going concern; the risk that, if ADVENTRX is unable to raise sufficient additional capital on a timely basis, certain terms of the offering announced on June 8, 2009 will prevent ADVENTRX from orderly winding-up its operations and require ADVENTRX to seek protection under the provisions of the U.S. Bankruptcy Code; the potential for regulatory authorities to require additional preclinical work and/or clinical activities to support regulatory filings, including prior to the submission or the approval of a New Drug Application for ANX-530 and ANX-514; the risk the FDA will determine that
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
4. ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
5. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
6. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
9. ADVENTRX Appoints Vice President of Commercialization
10. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
11. ADVENTRX Announces Consolidation of Clinical and Management Positions